One of India's largest diagnostic chains, running radiology, pathology and tele-radiology centres mostly under government PPP contracts.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 5 | 6 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | -217 | -17 | 671 | 727 | 799 | 877 | 916 | 976 |
| Borrowings | 246 | 474 | 41 | 32 | 160 | 202 | 284 | 531 |
| Other Liabilities | 596 | 146 | 149 | 134 | 197 | 188 | 287 | 295 |
| Total Liabilities | 630 | 609 | 877 | 909 | 1.2k | 1.3k | 1.5k | 1.8k |
| AssetsFixed Assets | 275 | 309 | 386 | 471 | 647 | 668 | 680 | 651 |
| CWIP | 9 | 4 | 28 | 25 | 10 | 3 | 30 | 208 |
| Investments | 0 | 0 | 0 | 0 | 0 | 32 | 32 | 58 |
| Other Assets | 345 | 297 | 463 | 413 | 514 | 581 | 761 | 902 |
| Total Assets | 630 | 609 | 877 | 909 | 1.2k | 1.3k | 1.5k | 1.8k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 61 | 38 | 119 | 129 | 75 | 24 | 89 | 134 |
| Cash from Investing | -201 | -77 | -67 | -241 | -109 | -129 | -102 | -391 |
| Cash from Financing | 145 | 6 | 20 | 176 | -33 | 84 | 14 | 278 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -42 | -39 | 50 | -2 | -59 | -169 | -21 | -80 |
| FCF Margin | — | — | — | — | — | — | — | — |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (30.7×) and current (23.2×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 5.4% growth and a 23× exit, ₹540 only delivers your return if you pay ₹293. The price is currently baking in 18% growth.
EPS grows 5.4%/yr for 5 years, then fades to 6% over 2, exits at 23×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 5.4% | 24.49 |
| FY28 | 5.4% | 25.82 |
| FY29 | 5.4% | 27.21 |
| FY30 | 5.4% | 28.68 |
| FY31 | 5.4% | 30.23 |
| FY32 | 5.7% ·fade | 31.95 |
| FY33 | 6.0% ·fade | 33.87 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.